Results 81 to 90 of about 28,066 (219)

Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing

Animal Research and One Health, EarlyView.
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley   +1 more source

Inhibiteurs de la PCSK9 : un nouveau traitement pour l’hypercholestérolémie [PDF]

, 2016
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appear to represent an important development in the management of hypercholesterolemia. US Food and Drug Administration and European Medicines Agency approved alirocumab and evolocumab,
Gencer, Baris, Rodondi, Nicolas, Mach, François   +2 more
core  

PCSK9 inhibitors

, 2015
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-C)
Mach, François, Lambert, Gilles, F Mach, G Lambert, Gencer, B, B Gencer   +5 more
core   +1 more source

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

International Journal of the Cardiovascular Academy
Hypercholesterolemia, a major contributor to atherosclerotic cardiovascular disease, remains inadequately controlled despite widespread statin use, particularly in patients with familial hypercholesterolemia or statin intolerance.
Agung Cendekia Putra Nusantara, Ariella Diandihati Rapsanjani, Ikhwan Handirosiyanto, Tara Mandiricha, Aisyah Silvia Gaffar   +4 more
doaj   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Genetic screening and response to drug therapy in familial hypercholesterolemia

Frontiers in Molecular Biosciences
ObjectivesFamilial hypercholesterolemia (FH) is an autosomal genetic disorder, which is significantly underdiagnosed. Here, we aimed to identify the genetic causes of a FH family and clarify the clinical diagnosis of the patient and then provide ...
Yuzhi Lu, Yuzhi Lu, Yuzhi Lu, Qianwen Chen, Qianwen Chen, Qianwen Chen, Qianwen Chen, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Wenjuan Zhang, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Jiangtao Dong, Lingfeng Zha, Lingfeng Zha, Lingfeng Zha   +17 more
doaj   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, EarlyView.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

Lipids in Health and Disease, 2008
Background Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating ...
Mbikay Majambu, LaHaye Stephen A, Lahey Karen A, Chaplin Anna, Cousins Marion, Raymond Angela, Dewpura Thilina, Mayne Janice, Ooi Teik, Chrétien Michel   +9 more
doaj   +1 more source

New developments in atherosclerosis: clinical potential of PCSK9 inhibition

, 2015
Ilaria Giunzioni, Hagai Tavori Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, Portland, OR, USA Abstract: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid ...
Giunzioni I, Tavori H
core  

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

International Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto, Martha Gulati, Suvarna S. Khadilkar, Angela H. E. M. Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R. Genazzani, Hema Divakar, Athena Poppas, on behalf of the World Heart Federation (WHF) and the International Federation of Gynecology and Obstetrics (FIGO)   +9 more
wiley   +1 more source